Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: A propensity score matching analysis

Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: A propensity score matching analysis

PurposeTo compare the efficacy and safety of transarterial chemoembolization (TACE) plus sorafenib and immune checkpoint inhibitors (T+S+ICIs) and TACE plus sorafenib (T+S) when treating patients with advanced hepatocellular carcinoma (HCC) who have previously received locoregional treatment.Materia...

Full description

Bibliographic Details
Main Authors: Xue-Gang Yang, Yan-Yuan Sun, Hai-Qing Wang, De-Shan Li, Guo-Hui Xu, Xiao-Qi Huang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Oncology
Subjects:
hepatocellular carcinoma
transarterial chemoembolization
sorafenib
immune checkpoint inhibitor
PD-1 inhibitor
combined therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.914385/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.914385/full

Similar Items